Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®).

Future oncology (London, England)·2026

Same author

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations.

American journal of hematology·2025

Same author

Pharmacokinetic profile of novel reduced-dose Danziten<sup>™</sup> (nilotinib tablets) versus Tasigna<sup>®</sup> (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis.

Cancer chemotherapy and pharmacology·2025

Same author

Recognition, prevention, and management of adverse events associated with asparaginase/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel.

Haematologica·2025

Same author

Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.

British journal of haematology·2024

Same author

Use of Socioeconomic Demographic Data in Studies on Pediatric Unilateral Hearing Loss: A Scoping Review.

Ear and hearing·2023

Same journal

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical advances in hematology & oncology : H&O·2026

Same journal

Active treatment in high-risk, early-stage CLL or SLL.

Clinical advances in hematology & oncology : H&O·2026

Same journal

Targeting human kallikrein 2 in prostate cancer.

Clinical advances in hematology & oncology : H&O·2026

Same journal

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Clinical advances in hematology & oncology : H&O·2026

Same journal

The development of second-generation KRAS inhibitors.

Clinical advances in hematology & oncology : H&O·2026

Same journal

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical advances in hematology & oncology : H&O·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 16, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

New developments in acute lymphoblastic leukemia.

Dan Douer, Deborah A Thomas¹

¹University of Texas, MD Anderson Cancer Center, Houston, Texas.

Clinical Advances in Hematology & Oncology : H&O

|March 14, 2015

Summary

This summary is machine-generated.

Treatment for acute lymphoblastic leukemia (ALL) is tailored by age and subtype, with survival improving due to risk-stratified chemotherapy and novel agents. Research explores intensive pediatric protocols for adults and new therapies for relapsed ALL.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Experiment Videos

Last Updated: Apr 16, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Area of Science:

Hematology
Oncology
Pediatric Oncology

Background:

Acute lymphoblastic leukemia (ALL) affects both children and adults, with recent decades showing improved survival rates for de novo cases.
Treatment strategies are increasingly personalized based on patient age, disease subtype, and risk stratification.

Purpose of the Study:

To review current frontline treatment approaches for acute lymphoblastic leukemia (ALL) across different age groups.
To highlight recent advancements and emerging therapies for relapsed ALL.

Main Methods:

Analysis of current treatment paradigms for pediatric, adolescent, young adult, and older adult patients with de novo ALL.
Review of recently approved and investigational agents for ALL, including novel chemotherapeutics, targeted therapies, and cell-based approaches.

Main Results:

Frontline ALL treatment involves risk-stratified chemotherapy, with children/young adults receiving intensified regimens and older adults benefiting from reduced-intensity regimens with targeted therapy.
Novel agents like clofarabine, nelarabine, and liposomal vincristine have been approved, and cell therapies and antibody-drug conjugates are under investigation.
Emerging data suggest the potential feasibility of intensive pediatric protocols in adult ALL patients.

Conclusions:

Tailored treatment strategies incorporating risk stratification and novel agents have significantly improved outcomes in de novo ALL.
Ongoing research into novel therapies holds promise for improving survival rates in relapsed and refractory ALL.
Personalized medicine, including the exploration of pediatric protocols in adults, is a key direction in advancing ALL treatment.